Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Biol Ther. 2022 Dec 31;23(1):134-135. doi: 10.1080/15384047.2022.2033058.
As precision oncology evolves toward developing more targeted therapies, sequencing has moved to the forefront of treatment decision-making. Whole genome sequencing (WGS) has emerged as a technology capable of identifying candidates for rare and targeted treatments. Yet, because the tumor is constantly evolving during relapse and therapy resistance, the frequency with which WGS should be performed to identify potential new therapies for progressing patients remains unknown. A recent study in by Van de Haar et al. observed a remarkably stable driver gene mutational profile among 250 biopsy pairs from 231 patients undergoing standard of care treatments during the biopsy interval. Their findings suggest that the actionable metastatic cancer genome is relatively stable over time and that a single WGS provides a complete view of the treatment opportunities available to most metastatic cancer patients.
随着精准肿瘤学向开发更具针对性的治疗方法发展，测序已成为治疗决策的前沿。全基因组测序（WGS）已成为一种能够识别罕见和靶向治疗候选者的技术。然而，由于肿瘤在复发和治疗耐药期间不断进化，因此仍不清楚为进展患者确定潜在新疗法时应进行多少次 WGS。Van de Haar 等人最近在[杂志名称]上发表的一项研究观察了 231 名患者的 250 对活检样本中 250 对活检样本中的驱动基因突变谱，这些患者在活检间隔期间接受标准治疗。他们的发现表明，可操作的转移性癌症基因组随时间相对稳定，单次 WGS 可提供大多数转移性癌症患者可用的治疗机会的完整视图。
